To hear about similar clinical trials, please enter your email below
Trial Title:
Biochemical Role of Circulating microRNAs Expression as Diagnostic Markers for Non-Hodgkin's Lymphoma Patients
NCT ID:
NCT05921812
Condition:
Non-Hodgkin Lymphoma
Conditions: Official terms:
Lymphoma
Lymphoma, Non-Hodgkin
Study type:
Observational [Patient Registry]
Overall status:
Recruiting
Study design:
Time perspective:
Cross-Sectional
Intervention:
Intervention type:
Diagnostic Test
Intervention name:
real time pcr
Description:
evaluate the expression of certain circulating microRNAs by real time pcr
Arm group label:
cases
Arm group label:
control
Summary:
Lymphomas are a fairly common malignancy accounting for approximately half of all newly
diagnosed hematological neoplasms, and they comprise the sixth most common group of
malignancies worldwide in both men and women, With marked geographic variations and
affecting more males than females within the age range of 1 to 85 years but peaking
within the second decades of life (Oluwasola AO et al., 2011, Roman E et al., 2011 and
Jemal A et al., 2010) . Lymphomas have traditionally been classified as either Hodgkin's
lymphoma (HL) or non-Hodgkin's lymphoma (NHL) based on the presence or absence of the
Reed-Sternberg (RS) cell on histology. (Fitzmaurice C et al., 2017). Non-Hodgkin's
lymphoma (NHLs) comprise a wide class of lymphoid neoplasms that evolve from the clonal
expansion of mature B, T and natural killer (NK) cells in different stages of development
(Morton, L.M. et al., 2014 and Schmitz R et al., 2009). NHLs are the most prevalent
hematopoietic neoplasms, accounting for approximately 4.3% of all cancer diagnoses (Sant,
M. et al., 2010) , Of them, B cell NHL accounts for approximately 30% of all lymphoid
neoplasms, followed by HL (8%) and T/NK neoplasms (5%) (Morton, L.M. et al., 2006).
MicroRNAs (miRNAs) are a class of small, naturally occurring, noncoding and
single-stranded RNA molecules (18, 22 nucleotides) that function as post-transcriptional
regulators by directly cleaving target messenger RNA (mRNA) or translational repression
(Bartel DP. Et al., 2004). The discovery of miRNA has exposed a new layer of gene
expression regulation that affects many physiological and pathological processes of life
(Lawrie CH. Et al., 2013).
Many abnormal miRNA expression patterns are found in various human malignancies, and
certain miRNAs play roles as oncogenes or tumor suppressors (Ling N et al., 2013).
Certain miRNAs have been found to characterize various subtypes of NHL and have important
roles in B-cell differentiation and lymphomagenesis (Zhang J et al., 2009, Malumbres R et
al., 2009, Basso K et al., 2009 and Auer RL et al., 2011). Recently, many studies had
shown that tumor cell-specific miRNAs were detectable in the plasma and serum of patients
with cancer. Therefore, miRNAs may be served as good biomarkers for early detection,
diagnosis, and follow up of patients with cancer (Cortez MA et al., 2012).
Criteria for eligibility:
Study pop:
Patients who have newly diagnosed, histo-pathologically proved Non-Hodgkin's
lymphoma,aged from 18-75 and healthy control of matched age and sex
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
1. This study will include patients who have newly diagnosed, histo-pathologically
proved Non-Hodgkin's lymphoma.
2. Age from 18 to 75 years old.
3. anti-neoplastic treatment naïve patients.
4. No associated other malignancies (neither Synchronous nor metachronous) than
Non-Hodgkin's lymphoma.
Exclusion Criteria:
1. children below 18 years old or elderly people more than 75 years old
2. patients not newly diagnosed with non-Hodgkin's lymphoma
3. presence of any associated other malignancies than non-Hodgkin's lymphoma
Gender:
All
Minimum age:
18 Years
Maximum age:
75 Years
Healthy volunteers:
Accepts Healthy Volunteers
Locations:
Facility:
Name:
Sohag University
Address:
City:
Sohag
Country:
Egypt
Status:
Recruiting
Contact:
Last name:
Magdy M Amin, Professor
Start date:
February 1, 2024
Completion date:
March 1, 2025
Lead sponsor:
Agency:
Sohag University
Agency class:
Other
Source:
Sohag University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05921812
